Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. (3rd September 2021)

• Record Type: Journal Article
• Authors: Poulos, Christine; Soliman, Ahmed M.; Tekin, Sibel; Agarwal, Sanjay K.
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 21:Number 5(2021)
• Page Start: 1091
• Page End: 1099
• Publication Date: 2021-09-03
• Subjects: Benefit-risk preferences -- discrete choice -- endometriosis -- pain -- risk tolerance; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1080/14737167.2021.1832468
• Languages: English
• ISSNs: 1473-7167

Abstract

ABSTRACT: Introduction: We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain. Area covered: Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating elagolix (150 mg/day and 200 mg/twice-daily dosages) and leuprolide for the treatment of moderate to severe endometriosis-related pain. Sensitivity analyses were conducted by varying the range of risk for pregnancy-related problems, moderate to severe hot flashes, and bone fracture across scenarios. Expert opinion: The 200 mg twice daily dosage of elagolix is more likely to be preferred over leuprolide by patients with moderate to severe endometriosis-related pain in all scenarios explored in the evaluation and sensitivity analyses. The probability that an average respondent would select a treatment was sensitive to increases in risk of moderate to severe hot flashes for leuprolide and possible variations in the risk of pregnancy-related problems for both treatments but was not influenced by an increased risk of bone fracture. Conclusions: Patients' preferences for treatment of endometriosis-related pain should be evaluated using the benefits and risks of each pharmacological option. Respondents were more likely to prefer the treatment profile similar to 200 mg twice daily elagolix over that of leuprolide in all scenarios.